Mission Statement, Vision, & Core Values (2024) of VBI Vaccines Inc. (VBIV)

An Overview of VBI Vaccines Inc. (VBIV)

General Summary of VBI Vaccines Inc.

VBI Vaccines Inc. (VBIV) was founded in 2010, focusing on the development and commercialization of innovative vaccines to address unmet needs in infectious diseases as well as certain cancers. The company is headquartered in Cambridge, Massachusetts.

VBIV's product pipeline includes its lead candidate, the enveloped virus-like particle (eVLP)-based vaccine platform, which is used for various infectious diseases. The company has developed several products, including Sci-B-Vac, a next-generation hepatitis B vaccine, and is also in various stages of development for vaccines targeting other infectious diseases.

As of 2024, VBI Vaccines reported a significant increase in sales, reaching approximately $28 million in total revenues, driven primarily by sales from Sci-B-Vac and ongoing clinical trials for other candidates.

Company's Financial Performance in Latest Financial Reports

In the latest financial report for Q2 2024, VBI Vaccines showcased impressive financial performance marked by record-breaking revenues. The total revenues for the quarter were approximately $12 million, which represents a year-over-year increase of 25%.

The main product, Sci-B-Vac, contributed to $10 million of the total revenue, with key markets reporting strong growth:

Additionally, the company reported total assets of approximately $100 million and a cash reserve of around $45 million, positioning itself well for upcoming clinical trials and commercial initiatives.

Introduction to VBI Vaccines Inc. as a Leader in the Industry

VBI Vaccines Inc. is recognized as one of the leading companies in the biotech vaccine development sector. The company's innovative approach to creating vaccines through its eVLP platform has garnered significant attention and investment, establishing it as a frontrunner in addressing both infectious diseases and immuno-oncology challenges.

In 2024, VBIV has been acknowledged for its contribution to public health, particularly through the successful launch of Sci-B-Vac in several markets. The upward trajectory of the company reflects its commitment to research and development.

To understand more about VBI Vaccines Inc. and its successful strategies, continued reader engagement is encouraged.

Mission Statement of VBI Vaccines Inc. (VBIV)

Mission Statement Overview

The mission statement of VBI Vaccines Inc. (VBIV) articulates the company's commitment to developing and commercializing innovative vaccines to address unmet medical needs. This statement acts as a guiding principle for the company's long-term goals, shaping its strategic direction and operations. It reflects the essence of the organization and serves as a framework for decision-making.

Core Component 1: Commitment to Innovation

VBI's mission encompasses a strong commitment to innovation in vaccine development. The company focuses on advancing its proprietary technology platforms, which are designed to create next-generation vaccines. In 2023, VBI reported investments totaling approximately $35 million into R&D to enhance its pipeline.

Their leading vaccine candidate, the Sci-B-Vac, demonstrated efficacy rates of up to 96% in clinical trials, showcasing the company’s innovative approach in tackling hepatitis B. The global hepatitis market was valued at approximately $3.2 billion in 2022 and is projected to grow at a CAGR of 3.5% from 2023 to 2030, emphasizing the potential impact of VBI's innovations.

Core Component 2: Focus on Quality

Quality is paramount to VBI’s mission statement. The company adheres to stringent regulatory standards to ensure that its vaccines are safe, effective, and produced with the highest quality. In 2023, VBI achieved compliance with the FDA’s Good Manufacturing Practice (GMP) regulations, ensuring that its facilities meet the highest standards of production.

The company’s commitment is reflected in its recent quality audits, which reported a 98% compliance rate across all manufacturing processes. Furthermore, VBI's track record shows that 100% of its vaccines have received regulatory approval, highlighting its unwavering focus on quality.

Core Component 3: Addressing Unmet Medical Needs

A critical element of VBI's mission is its dedication to addressing unmet medical needs. The company prioritizes vaccine development for diseases that lack effective preventive measures. In 2024, VBI plans to initiate a new trial for a flu vaccine aimed at a target market potentially exceeding $5 billion.

Data from the World Health Organization indicates that vaccines can reduce the incidence of influenza by 40-60% in the overall population. With over 1 billion cases of influenza reported annually, the opportunity to impact public health through innovative vaccines is significant.

Vision Statement of VBI Vaccines Inc. (VBIV)

Vision for Innovative Vaccine Solutions

The vision of VBI Vaccines Inc. (VBIV) is centered around its commitment to developing innovative vaccine solutions that address critical public health needs. This includes a focus on unique delivery mechanisms and broad vaccine coverage to combat infectious diseases. As of 2024, VBIV aims to leverage its proprietary technology platform, enveloped viruslike particle (eVLP) technology, to create next-generation vaccines.

Global Impact and Accessibility

VBI’s vision underscores the importance of making vaccines accessible globally, particularly in underserved populations. The company aspires to reduce the burden of infectious diseases, with a target to increase vaccine access by 30% in low- and middle-income countries by 2025.

Research and Development Leadership

VBIV envisions itself as a leader in vaccine research and development, aiming for a 25% increase in R&D investment by 2024. The focus will be on advancing clinical trials for its lead candidates. The goal is to expedite the journey from discovery to market.

Collaboration and Partnership

To realize its vision, VBIV aims to foster strategic collaborations and partnerships within the biotechnology sector. The company has set a goal to establish at least five new partnerships by 2024, focusing on co-development of innovative vaccine products.

• Partnership with major pharmaceutical companies
• Collaboration with academic institutions for research enhancement
• Engagement with non-profit organizations for community outreach

Commitment to Sustainability

VBI is committed to sustainable practices in its manufacturing processes and supply chain. By 2024, the company aims to reduce its carbon footprint by 15% through implementing more efficient technologies and practices.

Core Values of VBI Vaccines Inc. (VBIV)

Innovation

The core value of innovation at VBI Vaccines Inc. (VBIV) emphasizes the importance of creativity and developing cutting-edge solutions in the biopharmaceutical industry.

In 2024, VBI has invested approximately $15 million in research and development, focusing on novel vaccine platforms. This commitment has resulted in clinical advancements, such as the initiation of Phase 2 trials for their lead candidate, VBI-1901, targeting glioblastoma, which is expected to enroll over 300 patients by mid-2024.

Integrity

Integrity stands as a pillar in VBI's operational framework, guiding ethical practices and transparency.

In 2023, VBI achieved a 100% compliance rate in its annual internal audits, affirming its commitment to regulatory standards and ethical conduct. Furthermore, the company publicly discloses all clinical trial results, ensuring stakeholders have access to accurate and timely information.

Collaboration

Collaboration is crucial for VBI's progress, fostering partnerships for comprehensive solutions.

In 2024, VBI formed a strategic alliance with the University of Pennsylvania, which secured $10 million in funding aimed at advancing the development of next-generation vaccines. This collaboration will leverage academic expertise and industry resources to enhance research capabilities.

Excellence

Excellence reflects VBI's commitment to high-quality standards in its products and services.

VBI's manufacturing facilities met the stringent FDA standards, achieving a 98% quality compliance rating in 2023. The company also received the 'Best Biotech Company' award at the 2023 Global Biotech Innovation Awards, recognizing its outstanding contributions to the industry.

Accountability

Accountability underpins VBI's responsibility to stakeholders and patients alike.

In 2024, VBI implemented a comprehensive quarterly reporting system aimed at measuring clinical outcomes and financial performance. This initiative has improved stakeholder communications and maintained a shareholder return of approximately 15% year-to-date.

Commitment to Patients

VBI’s unwavering commitment to patients drives its mission to develop effective vaccines.

As of 2024, VBI has provided educational resources to over 100,000 healthcare professionals about vaccine advancements. Additionally, the company has pledged a 5% of net profits to patient advocacy groups, aiming to enhance patient support and awareness in the vaccine domain.